[Trastuzumab and blood-brain barrier].
Due to its large molecular weight trastuzumab is easily blocked by the intact blood brain-barrier or even when it's partly impaired in meningeal carcinomatosis or brain metastasis. Its penetration is facilitated by whole-brain-radiotherapy but trastuzumab only reaches rather low and most likely therapeutically inadequate levels in central nervous system after intravenous application. Further investigations with lapatinib are warrented.
Platini
Christian
C
Pôle cancérologie-hématologie-pneumologie, service d'oncologie, CHR Metz-Thionville. cplatini@wanadoo.fr
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000493:pharmacokinetics*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology* / Q000528:radiation effects; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D016371:Cranial Irradiation; D005260:Female; D006801:Humans; D008577:Meningeal Neoplasms / Q000556:secondary; D008970:Molecular Weight; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab